

IASLC Staging and Prognostic Factors Committee

Total Cases Submitted to the 8th Edition Database

By Data Source

Region	Number	%
Europe	46,560	49
Asia	41,705	44
North America	4,660	5
Australia	1,593	1.7
South America	190	0.3
TOTAL	94,708	100



From: Rami-Porta R, Bolejack V, Giroux D, et al. The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2014;9:1618-1624.



IASLC Staging and Prognostic Factors Committee

Number of Cases Analyzed in the 8th Edition Database

By Data Source, Diagnosed From 1999 Through 2010

Type of database	Retrospective	Prospective (EDC)	Total
Consortium	41,548	2,089	43,637
Registry	26,122		26,122
Surgical series	5,373	592	5,965
Institutional series		1,185	1,185
Institutional registries	208		208
Unknown		39	39
TOTAL	73,251	3,905	77,156



From: Rami-Porta R, Bolejack V, Giroux D, et al. The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2014;9:1618-1624.



IASLC Staging and Prognostic Factors Committee Recommendations Regarding 8th Edition T-Descriptors

Descriptor	7th edition	Proposal for 8th edition
≤ 1 cm	T1a	T1a
> 1 - 2 cm	T1a	T1b
> 2 - 3 cm	T1b	T1c
> 3 - 4 cm	T2a	T2a
> 4 - 5 cm	T2a	T2b
> 5 - 7 cm	T2b	T3
> 7 cm	T3	T4
Bronchus < 2 cm	T3	T2
Complete atelectasis/ pneumonitis	T3	T2
Diaphragm invasion	T3	T4
Mediastinal pleura	T3	-



From: Rami-Porta R, Bolejack V, Giroux D, et al. The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol 2014;9:1618-1624.



IASLC Staging and Prognostic Factors Committee Recommendations Regarding 8th Edition T-Descriptors Implications for Clinical Practice

Every cm counts; careful follow-up

Accurate tumour size measurement, important

Rules to measure tumour size

Rules to measure part-solid non-mucinous adenocarcinoma


Elastic stains for visceral pleura invasion

Prognosis refinement

Better stratification for clinical trials

Core IASLC Data in Support of Recommendations for T Survival of pathologically staged T1-T2 N0 R0 tumors according to size only, at 1-cm intervals.


by Size Only
pT1-2 N0 M0 R0 NSCLC



From: Rami-Porta R, Bolejack V, Crowley J, et al. Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2015;10:990-1003.

Core IASLC Data in Support of Recommendations for T Survival of clinically staged T1-T2 N0 tumors according to size only, at 1-cm intervals.

by Size Only
cT1-2 N0 M0 NSCLC




From: Rami-Porta R, Bolejack V, Crowley J, et al. Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2015;10:990-1003.

Core IASLC Data in Support of Recommendations for T Survival according to 7th edition and proposed T categories for pathologically staged T1-T4 N0 M0 R0 tumors.


7th Edition T Categories

PT1-4 N0M0R0 Cases
V.7 T Status



Proposed T Categories

PT1-4 N0M0R0 Cases
Proposed T Status




From: Rami-Porta R, Bolejack V, Crowley J, et al. Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2015;10:990-1003.



Core IASLC Data in Support of Recommendations for T Survival according to 7th edition and proposed T categories for clinically staged T1-T4 N0 M0 tumors.


7th Edition T Categories

CT1-4 N0M0 Cases
V.7 T Status




Proposed T Categories

CT1-4 N0M0 Cases
Proposed T Status




From: Rami-Porta R, Bolejack V, Crowley J, et al. Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2015;10:990-1003.




IASLC Staging and Prognostic Factors Committee

T categories for the new types of adenocarcinomas



**Adenocarcinoma
in situ**




**Minimally invasive
adenocarcinoma**

From: Travis WD, Asamura H, Bankier A, et al. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2016; 11:1204-1223.

IASLC Staging and Prognostic Factors Committee Recommendations Regarding Size Measurement in Part-Solid Non-Mucinous Adenocarcinoma

**Clinical size:
size of
solid component**

**Pathologic size:
size of
invasive component**



From: Travis WD, Asamura H, Bankier A, et al. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2016; 11:1204-1223.


IASLC Staging and Prognostic Factors Committee Recommendations Regarding Size Measurement After Induction Therapy

Pathologic size:

**Multiply the percentage of viable cells
by the total size of the tumor**

*From: Travis WD, Asamura H, Bankier A, et al. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2016; 11:1204-1223.*

IASLC Staging and Prognostic Factors Committee Recommendations Regarding Subclassification of Visceral Pleural Involvement



PL0:	----
PL1 y PL2:	T2
PL3:	T3

In case of doubt about
the visceral pleura
involvement,
the use of elastic stains
is recommended

Copyright © 2008 Aletta Ann Frazier, MD


IASLC Staging and Prognostic Factors Committee Recommendations Regarding 8th Edition N-Descriptors

- Present N descriptors remain the same
- Quantification of nodal disease is recommended for further study:
 - pN1a: involvement of single pN1 nodal station
 - pN1b: involvement of multiple pN1 nodal stations
 - pN2a1: involvement of single pN2 nodal station without pN1 (skip pN2)
 - pN2a2: involvement of single pN2 nodal station with pN1
 - pN2b: involvement of multiple pN2 nodal stations
 - pN3: as it is

*From: Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2015; 10:1675-1684.*



Core IASLC Data in Support of Recommendations for N Survival curves for cN0, cN1, cN2, and cN3, T-any M0 tumors




N3 vs N2 vs N1 vs N0 Comparisons Adjusted for Histology (adeno vs others), Sex, Age 60+, and Region (Cox PH regression)

comparison	HR	P
N1 vs N0	1.68	<0.0001
N2 vs N1	1.42	<0.0001
N3 vs N2	1.38	<0.0001

From: Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2015; 10:1675-1684.

Core IASLC Data in Support of Recommendations for N Regarding Quantification of Nodal Disease for Further Study



N1 Single = N1a
N1 Multiple = N1b
N2 Single N2 (“skip mets”) = N2a1
N2 Single N2 + N1 = N2a2
N2 Multiple N2 = N2b

IASLC Staging and Prognostic Factors Committee Recommendations Regarding 8th Edition N-Descriptors Implications for Clinical Practice

- The amount of nodal disease has prognostic impact
- Important to quantify nodal disease both at clinical and pathologic staging
- Upfront resection for single station cN2?
- Prognosis refinement
- Better stratification

IASLC Staging and Prognostic Factors Committee Recommendations Regarding 8th Edition M-Descriptors


Descriptor	7th edition	Proposal for 8th edition
Intrathoracic metastasis (pleural/pericardial effusion, contralateral/bilateral tumor nodules, pleural/pericardial nodules)	M1a	M1a
Single extrathoracic metastatic lesion	M1b	M1b
Multiple extrathoracic lesions	M1b	M1c

IASLC Staging and Prognostic Factors Committee Recommendations Regarding 8th Edition M-Descriptors Implications for Clinical Practice

- **Number of metastatic lesions appears to be more important than location**
- **M1b: baseline definition of oligometastases and oligoprogression**
- **Prognosis refinement**
- **Better stratification**




*From: Eberhardt WE, Mitchell A, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2015;10:1515–1522.*




Core IASLC Data in Support of Recommendations for M Prognostic Impact of M1a Descriptors

Survival By M1a Descriptor
M1a Cases from EDC Only




Core IASLC Data in Support of Recommendations for M Single Lesion at Single Site by Organ

7th Edition M1b - Single Lesion at Single Site
By Organ
EDC Data Only



Core IASLC Data in Support of Recommendations for M Multiple Lesions at Single Site by Organ

7th Edition M1b - Multiple Lesions at Single Site
By Organ
EDC Data Only




From: Eberhardt WE, Mitchell A, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2015;10:1515–1522.




Core IASLC Data in Support of Recommendations for M The 7th Edition and Proposed 8th Edition M Categories


7th Edition M Categories
EDC Data Only



Proposed 8th Edition M Categories
EDC Data Only



From: Eberhardt WE, Mitchell A, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2015;10:1515–1522.



IASLC Staging and Prognostic Factors Committee Recommendations Regarding 8th Edition TNM for Lung Cancers With Multiple Lesions

- **Multiple primary tumors:
One TNM for each tumor**
- **Separate tumor nodules:
T3, T4, M1a**
- **Multiple adenocarcinomas with
GGO/lepidic features:
Highest T (#/m) N M**
- **Pneumonic type adenocarcinoma:
T3, T4, M1a**

IASLC Staging and Prognostic Factors Committee Recommendations Regarding 8th Edition Stage Groupings

	N0	N1	N2	N3	M1a any N	M1b any N	M1c any N
T1a	IA1	IIB	IIIA	IIIB	IVA	IVA	IVB
T1b	IA2	IIB	IIIA	IIIB	IVA	IVA	IVB
T1c	IA3	IIB	IIIA	IIIB	IVA	IVA	IVB
T2a	IB	IIB	IIIA	IIIB	IVA	IVA	IVB
T2b	IIA	IIB	IIIA	IIIB	IVA	IVA	IVB
T3	IIB	IIIA	IIIB	IIIC	IVA	IVA	IVB
T4	IIIA	IIIA	IIIB	IIIC	IVA	IVA	IVB


From: Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:39-51.



Recursive partitioning and amalgamation-generated survival tree based on best stage for 25,911 M0 training set cases.

T and N categories are modeled as ordered variables.

Stratified hazard ratios are given relative to the leftmost terminal node, T1aN0.




From: Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:39-51.

Core IASLC Data in Support of Recommendations for Stage Groupings


Overall Survival by Clinical Stage

7th Edition Stage Groupings



7 th Ed.	Events / N	MST	24 Month	60 Month
IA	1119 / 6303	NR	93%	82%
IB	768 / 2492	NR	85%	66%
IIA	424 / 1008	66.0	74%	52%
IIB	382 / 824	49.0	64%	47%
IIIA	2139 / 3344	29.0	55%	36%
IIIB	2101 / 2624	14.1	34%	19%
IV	664 / 882	8.8	17%	6%

Proposed Stage Groupings



Proposed	Events / N	MST	24 Month	60 Month
IA1	68 / 781	NR	97%	92%
IA2	505 / 3105	NR	94%	83%
IA3	546 / 2417	NR	90%	77%
IB	560 / 1928	NR	87%	68%
IIA	215 / 585	NR	79%	60%
IIB	605 / 1453	66.0	72%	53%
IIIA	2052 / 3200	29.3	55%	36%
IIIB	1551 / 2140	19.0	44%	26%
IIIC	831 / 986	12.6	24%	13%
IVA	336 / 484	11.5	23%	10%
IVB	328 / 398	6.0	10%	0%

- **MST, median survival time.**
- **Survival is weighted by type of database submission: registry versus other.**




From: Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:39-51.



Core IASLC Data in Support of Recommendations for Stage Groupings


Overall Survival by Pathologic Stage

7th Edition Stage Groupings



7 th Ed.	Events / N	MST	24 Month	60 Month
IA	1837 / 11423	NR	94%	83%
IB	2168 / 7711	NR	87%	71%
IIA	1514 / 3702	NR	77%	57%
IIB	1325 / 2776	58.9	70%	49%
IIIA	3467 / 5818	35.0	61%	36%
IIIB	364 / 506	20.0	45%	23%

Proposed Stage Groupings



Proposed	Events / N	MST	24 Month	60 Month
IA1	139 / 1389	NR	97%	90%
IA2	823 / 5633	NR	94%	85%
IA3	875 / 4401	NR	92%	80%
IB	1618 / 6095	NR	89%	73%
IIA	556 / 1638	NR	82%	65%
IIB	2175 / 5226	NR	76%	56%
IIIA	3219 / 5756	41.9	65%	41%
IIIB	1215 / 1729	22.0	47%	24%
IIIC	55 / 69	11.0	30%	12%

- **MST, median survival time.**
- **Survival is weighted by type of database submission: registry versus other.**




From: Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:39-51.




Core IASLC Data in Support of Recommendations for Stage Groupings

Internal Validation: Clinical TNM Stage Within Histologic Types


Adenocarcinoma



Squamous Cell



Other Histologies



cgrp6	Events / N	MST	24 Month	60 Month
IA1	47 / 678	NR	98%	94%
IA2	355 / 2521	NR	95%	86%
IA3	343 / 1818	NR	92%	81%
IB	331 / 1239	NR	89%	71%
IIA	98 / 299	NR	85%	64%
IIB	273 / 670	67.0	76%	53%
IIIA	731 / 1203	34.0	61%	37%
IIIB	422 / 655	27.0	53%	32%
IIIC	233 / 292	14.0	30%	17%
IVA	158 / 254	15.1	29%	11%
IVB	178 / 220	7.1	12%	0%

cgrp6	Events / N	MST	24 Month	60 Month
IA1	14 / 78	NR	95%	82%
IA2	90 / 397	NR	92%	76%
IA3	145 / 422	NR	81%	62%
IB	166 / 533	NR	84%	65%
IIA	81 / 212	NR	76%	58%
IIB	251 / 592	66.0	72%	52%
IIIA	717 / 1173	30.8	55%	40%
IIIB	650 / 868	17.4	41%	22%
IIIC	291 / 340	11.0	20%	16%
IVA	127 / 153	8.3	12%	7%
IVB	80 / 96	4.0	8%	.

cgrp6	Events / N	MST	24 Month	60 Month
IA1	7 / 25	NR	91%	62%
IA2	60 / 187	NR	86%	66%
IA3	58 / 177	NR	81%	66%
IB	63 / 156	68.0	75%	56%
IIA	36 / 74	47.0	61%	48%
IIB	81 / 191	67.0	62%	53%
IIIA	604 / 824	17.5	43%	29%
IIIB	479 / 617	13.8	35%	23%
IIIC	307 / 354	8.9	25%	6%
IVA	51 / 77	12.6	24%	20%
IVB	70 / 82	3.7	8%	.




From: Dettnerbeck F, Chansky K, Groome P, et al. The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of Non-Small Cell Lung Cancer in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2016; 11: 1433-1446.




Core IASLC Data in Support of Recommendations for Stage Groupings

Internal Validation: Pathologic TNM Stage Within Histologic Types


Adenocarcinoma



Squamous Cell



Other




pggrp6	Events / N	MST	24 Month	60 Month
IA1	89 / 1098	NR	97%	92%
IA2	490 / 4358	NR	96%	88%
IA3	474 / 3119	NR	94%	85%
IB	911 / 3942	NR	92%	77%
IIA	218 / 745	NR	87%	71%
IIB	985 / 2497	NR	80%	58%
IIIA	1719 / 3173	45.0	69%	42%
IIIB	649 / 924	25.0	51%	24%
IIIC	34 / 44	16.0	39%	8%

pggrp6	Events / N	MST	24 Month	60 Month
IA1	34 / 192	NR	96%	83%
IA2	241 / 887	NR	89%	71%
IA3	287 / 933	NR	86%	68%
IB	537 / 1659	NR	84%	68%
IIA	256 / 697	NR	79%	61%
IIB	929 / 2155	71.9	75%	54%
IIIA	1113 / 1918	35.0	59%	39%
IIIB	424 / 612	21.0	44%	26%
IIIC	16 / 18	9.0	11%	11%

pggrp6	Events / N	MST	24 Month	60 Month
IA1	16 / 99	NR	90%	81%
IA2	92 / 388	NR	91%	72%
IA3	114 / 349	NR	85%	67%
IB	170 / 494	NR	80%	63%
IIA	82 / 196	NR	75%	57%
IIB	261 / 574	67.0	66%	52%
IIIA	387 / 665	32.0	57%	38%
IIIB	142 / 193	16.0	34%	19%
IIIC	5 / 7	6.0	29%	29%




From: Dettnerbeck F, Chansky K, Groome P, et al. The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of Non-Small Cell Lung Cancer in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2016; 11: 1433-1446.




Core IASLC Data in Support of Recommendations for Stage Groupings External Validation

The objective of external validation was to apply the proposed revised staging criteria to an external database. The external database chosen was the National Cancer Database (NCDB) of the American College of Surgeons Committee on Cancer. Survival by best stage is shown for the NCDB and IASLC databases, according to proposed stage groupings.



TNM	Events / N	MST	24 Month	60 Month
IA1	2688 / 8572	103.3	86%	68%
IA2	16417 / 43887	83.3	83%	61%
IA3	15627 / 34557	66.1	76%	53%
IB	19570 / 39922	59.2	73%	49%
IIA	7223 / 12912	42.4	64%	41%
IIB	27759 / 45984	34.6	60%	36%
IIIA	79047 / 102433	17.0	40%	20%
IIIB	66417 / 77271	10.7	26%	10%
IIIC	16350 / 18295	8.9	20%	7%
IV	369433 / 396461	4.9	11%	3%



TNM	Events / N	MST	24 Month	60 Month
IA1	173 / 1765	NR	96%	89%
IA2	923 / 6127	NR	94%	82%
IA3	931 / 4606	NR	90%	78%
IB	1726 / 6400	NR	87%	71%
IIA	583 / 1700	NR	81%	64%
IIB	2307 / 5537	72.0	75%	55%
IIIA	4703 / 7779	35.0	60%	37%
IIIB	2553 / 3473	19.0	43%	22%
IIIC	873 / 1026	11.0	23%	11%
IV	665 / 883	8.7	17%	6%




Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2017; 12:1109-1121.




Core IASLC Data in Support of Recommendations for Small Cell Lung Cancer Overall Survival by Clinical T Category

7th Edition T Categories



cT 7 th Ed.	Events / N	MST	12 Month	24 Month
T1a	39 / 104	NR	96%	72%
T1b	25 / 68	NR	89%	74%
T2a	34 / 68	33.0	89%	61%
T2b	12 / 24	20.2	68%	49%
T3	21 / 35	21.5	75%	45%
T4	800 / 966	12.0	49%	21%

Proposed T Categories




cT Proposed	Events / N	MST	12 Month	24 Month
T1a	5 / 20	NR	100%	90%
T1b	34 / 84	NR	95%	68%
T1c	25 / 68	NR	89%	74%
T2a	26 / 53	33.0	94%	64%
T2b	8 / 17	NR	75%	56%
T3	26 / 44	21.5	71%	48%
T4	807 / 979	12.0	50%	21%

Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:300-311.

Core IASLC Data in Support of Recommendations for Small Cell Lung Cancer Overall Survival by Clinical N Category


8th Edition N Categories



Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:300-311.


Core IASLC Data in Support of Recommendations for Small Cell Lung Cancer Overall Survival by Single Versus Multiple Metastatic Sites

Single vs Multiple Metastatic Sites




Mets Sites	Events / N	MST	12 Month	24 Month
Single Site	308 / 336	7.2	25%	6%
Multiple Sites	185 / 205	5.9	20%	7%

Brain Only vs Single vs Multiple Metastatic Sites




SSM	Events / N	MST	12 Month	24 Month
Brain Only	38 / 47	9.5	36%	8%
Other Single	270 / 289	6.8	23%	5%
Multiple Sites	185 / 205	5.9	20%	7%

Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:300-311.




Core IASLC Data in Support of Recommendations for Small Cell Lung Cancer Overall Survival by Clinical Stage

7th Edition Stage Groupings



cTNM			12	24
7 th Ed.	Events / N	MST	Month	Month
IA	45 / 129	NR	95%	75%
IB	22 / 42	32.4	90%	63%
IIA	10 / 28	41.0	96%	66%
IIB	10 / 14	15.0	69%	38%
IIIA	203 / 270	15.7	59%	32%
IIIB	641 / 782	12.0	49%	20%
IV	2620 / 2926	7.3	27%	8%

Proposed Stage Groupings



cTNM			12	24
Proposed	Events / N	MST	Month	Month
IA1	3 / 14	NR	100%	93%
IA2	27 / 67	NR	97%	68%
IA3	15 / 48	NR	91%	80%
IB	16 / 32	33.0	93%	67%
IIA	6 / 10	24.1	80%	50%
IIB	17 / 38	28.0	87%	56%
IIIA	191 / 254	15.6	58%	32%
IIIB	326 / 402	12.6	52%	22%
IIIC	330 / 400	11.4	48%	19%
IV	2620 / 2926	7.3	27%	8%

Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:300-311.

